multiple sclerosis
Neurology · 2006–2025
45decisions
20medicines
24carried consumer input
132individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ocrelizumab Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). | Jul 2025 | Recommended with restriction | 14 individuals MS Australia · Neuroimmunology Group |
| ublituximab Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). | May 2025 | Recommended with restriction | 1 individuals MS Australia |
| natalizumab Treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS) to delay the progression of physical disability and reduce the frequency of… | Mar 2025 | Recommended | none received |
| ofatumumab Treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients to delay progression of physical disability and reduce frequency of relapse. | Mar 2024 | Not recommended | input received MS Australia |
| fingolimod, ofatumumab, siponimod Amendment to PBS listings to allow nurse practitioners (NPs) to initiate and continue treatment of fingolimod, ofatumumab, and siponimod in consultation with a… | Nov 2024 | Recommended with restriction | input received Sclerosis Nurses Australasia · MS Australia |
| natalizumab Treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS). | Mar 2023 | Recommended | 8 individuals |
| cladribine Treatment of relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical disability. | Nov 2023 | Not recommended | none received |
| natalizumab Treatment of clinically definite relapsing-remitting multiple sclerosis to delay progression of physical disability and reduce frequency of relapse. | Jul 2022 | Recommended | none received |
| diroximel fumarate Treatment of relapsing-remitting multiple sclerosis (RRMS). | Mar 2022 | Recommended with restriction | 6 individuals MS Australia |
| glatiramer acetate Treatment of multiple sclerosis using a new pre-filled pen formulation as an alternative to the existing pre-filled syringe formulation. | Mar 2022 | Recommended | 1 individuals MS Australia |
| glatiramer acetate Treatment of relapsing-remitting multiple sclerosis, including reduction of frequency of relapses and treatment of patients with a single clinical event… | Mar 2021 | Recommended | none received |
| tetracosactide Derestriction of tetracosactide for treatment of hypsarrhythmia and/or infantile spasms, and expansion to include acute exacerbations in patients with multiple… | Mar 2021 | Deferred | none received |
| ofatumumab Treatment of relapsing-remitting multiple sclerosis (RRMS) in patients with clinically definite disease diagnosed by MRI and/or spinal cord imaging, with at… | Mar 2021 | Recommended with restriction | 4 individuals MS Australia |
| cladribine Treatment of relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and delay the progression of physical disability. | Nov 2021 | Not recommended | 1 individuals |
| ozanimod Treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS). | Sep 2020 | Deferred | input received MS Australia |
| siponimod Treatment of relapse-onset phenotypes of multiple sclerosis (MS), including secondary progressive MS (SPMS) in patients with prior history of… | Jul 2020 | Recommended with restriction | 2 individuals |
| nabiximols Adjunctive treatment of moderate to severe spasticity in patients with multiple sclerosis who have not adequately responded to oral anti-spasticity agents. | Mar 2020 | Not recommended | 4 individuals |
| fingolimod Treatment of relapsing-remitting multiple sclerosis in paediatric and low-weight patients (≤40 kg). | Jul 2019 | Recommended | input received |
| dimethyl fumarate Treatment of patients with relapsing-remitting multiple sclerosis (RRMS). | Nov 2019 | Recommended with restriction | none received |
| cladribine Treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical… | Jul 2018 | Not recommended | 8 individuals MS Research Australia · Carers Australia |
| cladribine Treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical… | Mar 2018 | Not recommended | 26 individuals MS Research Australia · Trish Multiple Sclerosis Research Foundation |
| glatiramer acetate Treatment of clinically isolated syndrome suggestive of multiple sclerosis in patients thought to be at high risk of subsequent diagnosis with clinically… | Jul 2017 | Not recommended | input received MS Australia · MS Research Australia |
| ocrelizumab Treatment of relapsing-remitting multiple sclerosis (RRMS) to suppress clinical relapses, delay disability progression, and reduce subclinical measures of… | Jul 2017 | Recommended with restriction | 10 individuals MS Australia · MS Research Australia |
| cladribine Treatment of relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical disability. | Nov 2017 | Not recommended | 5 individuals MS Australia · MS Research Australia |
| daclizumab Treatment of relapsing-remitting multiple sclerosis (RRMS) in patients with clinically definite disease diagnosed by MRI and at least 2 documented attacks in… | Jul 2016 | Deferred | input received |
| dimethyl fumarate Treatment of patients with relapsing-remitting multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability. | Jul 2016 | Recommended | input received |
| teriflunomide Treatment of patients with relapsing forms of multiple sclerosis, specifically relapsing-remitting multiple sclerosis (RRMS). | Nov 2016 | Not recommended | none received |
| glatiramer acetate Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients. | Mar 2015 | Recommended | input received |
| alemtuzumab Treatment of relapsing-remitting multiple sclerosis (RRMS) in patients with active disease defined by clinical or imaging features to slow the accumulation of… | Jul 2014 | Recommended with restriction | 40 individuals |
| fampridine Symptomatic improvement of walking ability in ambulatory patients with clinically definite multiple sclerosis who meet specified criteria (EDSS score 4–7,… | Mar 2014 | Not recommended | unclear |
| alemtuzumab Treatment of relapsing-remitting multiple sclerosis (RRMS), either as a first-line therapy in patients with poor prognostic signs or as escalation therapy in… | Nov 2014 | Not recommended | 2 individuals |
| peginterferon beta-1a First-line treatment of patients with remitting, relapsing multiple sclerosis. | Nov 2014 | Recommended with restriction | input received |
| dimethyl fumarate Treatment of relapsing-remitting multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability. | Jul 2013 | Recommended | no section in document |
| nabiximols Treatment of moderate to severe spasticity due to multiple sclerosis in patients who are intolerant to anti-spasticity medication and/or have not adequately… | Jul 2013 | Not recommended | unclear |
| teriflunomide Initial and continuing treatment of relapsing-remitting multiple sclerosis (RRMS) in ambulatory patients who have experienced at least 2 documented attacks of… | Jul 2013 | Recommended with restriction | unclear |
| fampridine Symptomatic improvement of walking ability in ambulatory patients with clinically definite multiple sclerosis. | Nov 2012 | Not recommended | unclear |
| teriflunomide Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients who have experienced at least 2… | Nov 2012 | Not recommended | unclear |
| teriflunomide Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients who have experienced at least 2… | Nov 2012 | Not recommended | unclear |
| fampridine Symptomatic improvement of walking ability in ambulatory patients with clinically definite multiple sclerosis. | Nov 2012 | Not recommended | unclear |
| cladribine Initial and continuing treatment of relapsing-remitting multiple sclerosis (RRMS) in ambulatory patients who have experienced at least two documented attacks… | Mar 2011 | Not recommended | no section in document |
| fingolimod Initial and continuing treatment of clinically relapsing-remitting multiple sclerosis (RRMS) in ambulatory patients who have experienced at least 2 documented… | Mar 2011 | Recommended with restriction | unclear |
| interferon beta-1b Treatment of relapsing-remitting multiple sclerosis in ambulatory patients diagnosed using the McDonald criteria, including patients with a single clinical… | Mar 2007 | Not recommended | no section in document |
| interferon beta-1b Initial treatment of relapsing-remitting multiple sclerosis in ambulatory patients who have experienced documented neurological dysfunction, with eligibility… | Mar 2007 | Not recommended | no section in document |
| natalizumab Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients eighteen years of age or older. | Nov 2006 | Recommended with restriction | no section in document |
| natalizumab Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients eighteen years of age or older. | Nov 2006 | Recommended with restriction | no section in document |
Who spoke
MS Australia · MS Research Australia · Carers Australia · Sclerosis Nurses Australasia · Trish Multiple Sclerosis Research Foundation · Neuroimmunology Group
What the PBS pays
$691M in government benefit over 2024–25, across 300,045 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ocrelizumab | $248.8M |
| fingolimod, ofatumumab, siponimod | $143.2M |
| ofatumumab | $93.3M |
| cladribine | $81.9M |
| natalizumab | $37.8M |
| fingolimod | $37M |
| siponimod | $12.9M |
| dimethyl fumarate | $9.8M |
| glatiramer acetate | $5.5M |
| ozanimod | $4.4M |
| peginterferon beta-1a | $3.8M |
| diroximel fumarate | $2.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 17 technologies for this condition, recommending 16 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| natalizumabNatalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy | TA1126 | recommended restricted | 2026-01 |
| cladribineCladribine for treating active relapsing forms of multiple sclerosis | TA1053 | recommended restricted | 2025-04 |
| ublituximabUblituximab for treating relapsing multiple sclerosis | TA1025 | recommended restricted | 2024-12 |
| diroximel fumarateDiroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | recommended restricted | 2022-06 |
| ponesimodPonesimod for treating relapsing–remitting multiple sclerosis | TA767 | recommended restricted | 2022-02 |
| ozanimodOzanimod for treating relapsing–remitting multiple sclerosis | TA706 | not recommended | 2021-06 |
| ofatumumabOfatumumab for treating relapsing multiple sclerosis | TA699 | recommended restricted | 2021-05 |
| siponimodSiponimod for treating secondary progressive multiple sclerosis | TA656 | recommended restricted | 2020-11 |
| peginterferon beta 1aPeginterferon beta-1a for treating relapsing–remitting multiple sclerosis | TA624 | recommended | 2020-02 |
| cladribineCladribine for treating relapsing–remitting multiple sclerosis | TA616 | recommended restricted | 2019-12 |
| ocrelizumabOcrelizumab for treating relapsing–remitting multiple sclerosis | TA533 | recommended restricted | 2018-07 |
| beta interferons and glatiramer acetateBeta interferons and glatiramer acetate for treating multiple sclerosis | TA527 | recommended restricted | 2018-06 |
Showing the 12 most recent of 17.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| interferon betaAVONEX PEN | 2002 | 9 |
| peginterferon betaPLEGRIDY peginterferon beta-1a (rch) 125 microgram/0.5 mL solution for | 2014 | 6 |
| tolebrutinibCENRIFKI tolebrutinib 60mg film coated tablet blister pack | 2026 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 24 of 32 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.